Toronto Dominion Bank increased its position in shares of Iqvia Holdings Inc (NYSE:IQV) by 15.1% in the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 111,876 shares of the medical research company’s stock after acquiring an additional 14,690 shares during the quarter. Toronto Dominion Bank’s holdings in Iqvia were worth $16,089,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors have also recently bought and sold shares of IQV. Oregon Public Employees Retirement Fund raised its stake in shares of Iqvia by 44,777.1% during the 4th quarter. Oregon Public Employees Retirement Fund now owns 7,140,389 shares of the medical research company’s stock worth $61,000 after acquiring an additional 7,124,478 shares in the last quarter. FMR LLC raised its stake in shares of Iqvia by 41.1% during the 4th quarter. FMR LLC now owns 4,217,991 shares of the medical research company’s stock worth $490,004,000 after acquiring an additional 1,228,148 shares in the last quarter. Norges Bank bought a new position in shares of Iqvia during the 4th quarter worth approximately $124,606,000. Boston Partners raised its stake in shares of Iqvia by 417.6% during the 4th quarter. Boston Partners now owns 1,315,752 shares of the medical research company’s stock worth $152,851,000 after acquiring an additional 1,061,550 shares in the last quarter. Finally, BlackRock Inc. raised its stake in shares of Iqvia by 3.2% during the 4th quarter. BlackRock Inc. now owns 10,977,184 shares of the medical research company’s stock worth $1,275,219,000 after acquiring an additional 342,256 shares in the last quarter. Hedge funds and other institutional investors own 91.47% of the company’s stock.
IQV has been the subject of several recent analyst reports. TheStreet lowered shares of Iqvia from a “b” rating to a “c+” rating in a research note on Wednesday, May 1st. Piper Jaffray Companies boosted their price objective on shares of Iqvia to $148.00 and gave the stock a “neutral” rating in a research note on Friday, February 15th. Zacks Investment Research upgraded shares of Iqvia from a “sell” rating to a “hold” rating in a research note on Friday, May 3rd. UBS Group set a $170.00 price objective on shares of Iqvia and gave the stock a “buy” rating in a research note on Friday, February 15th. Finally, Barclays reissued a “buy” rating and set a $155.00 target price on shares of Iqvia in a research report on Friday, February 15th. Four analysts have rated the stock with a hold rating, thirteen have issued a buy rating and two have issued a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average price target of $146.88.
NYSE:IQV traded down $0.40 during trading hours on Friday, hitting $134.84. 28,977 shares of the company were exchanged, compared to its average volume of 1,179,759. The company has a market cap of $26.68 billion, a PE ratio of 26.43, a P/E/G ratio of 1.64 and a beta of 0.80. Iqvia Holdings Inc has a 52-week low of $97.40 and a 52-week high of $146.10. The company has a current ratio of 1.14, a quick ratio of 1.14 and a debt-to-equity ratio of 1.69.
Iqvia (NYSE:IQV) last released its quarterly earnings data on Wednesday, May 1st. The medical research company reported $1.53 EPS for the quarter, beating the consensus estimate of $1.41 by $0.12. The business had revenue of $2.68 billion for the quarter, compared to the consensus estimate of $2.67 billion. Iqvia had a net margin of 2.35% and a return on equity of 15.08%. The business’s revenue for the quarter was up 4.7% on a year-over-year basis. During the same period in the prior year, the firm earned $1.34 EPS. As a group, analysts expect that Iqvia Holdings Inc will post 5.88 EPS for the current fiscal year.
In other news, Director Group Holdings (Sbs) Advis Tpg sold 4,044,480 shares of the company’s stock in a transaction on Friday, March 8th. The shares were sold at an average price of $140.80, for a total value of $569,462,784.00. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider W Richard Staub sold 27,025 shares of the company’s stock in a transaction on Wednesday, February 20th. The shares were sold at an average price of $140.54, for a total transaction of $3,798,093.50. The disclosure for this sale can be found here. Insiders sold a total of 4,214,778 shares of company stock worth $593,327,768 over the last ninety days. Insiders own 6.00% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This story was originally reported by Stock Observer and is owned by of Stock Observer. If you are viewing this story on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark legislation. The correct version of this story can be viewed at https://www.thestockobserver.com/2019/05/17/iqvia-holdings-inc-iqv-position-lifted-by-toronto-dominion-bank.html.
IQVIA Holdings Inc provides advanced analytics, technology solutions, and contract research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
Featured Article: What is a short straddle?
Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Iqvia Holdings Inc (NYSE:IQV).
Receive News & Ratings for Iqvia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia and related companies with MarketBeat.com's FREE daily email newsletter.